Diabetic retinopathy (DR) is an inflammatory and progressive vaso-occlusive disease resulting in angiogenesis. Galectin-1 is a hypoxia-induced angiogenic factor associated with cancer and proliferative DR. Here we reveal a significant upregulation of galectin-1 in eyes of DR patients along with progression of clinical stages beginning from the pre-ischemic, inflammatory stage with diabetic macular edema, but not in eyes with non-diabetic retinal vascular occlusions. As for its regulatory mechanism unrelated to hypoxia but selective to DR, in vitro galectin-1/LGALS1 expression was shown to increase after application to Müller glial cells with interleukin (IL)-1β, which was induced in monocyte-derived macrophages and microglial cells via toll-like receptor (TLR) 4 signaling stimulated by advanced glycation endproducts (AGE). In vivo inhibition of AGE generation with aminoguanidine, macrophage depletion with clodronate liposomes, and antibody-based blockade of Il-1β and Tlr4 attenuated diabetes-induced retinal Lgals1 expression in mice. Fibrovascular tissues from proliferative DR eyes were immunoreactive for AGE, TRL4 and IL-1β in macrophages, and IL-1β receptor-positive glial cells expressed galectin-1. Therefore, diabetes-induced retinal AGE accumulation was suggested to activate IL-1β-related inflammatory cues in macrophages followed by Müller cells, linking to galectin-1 upregulation in human DR with time. Our data highlight AGE-triggered inflammation as the DRselective inducer of galectin-1.
control to slow the disease progression, and the intravitreal injection of VEGF blockers is a first-line treatment for DME; however, the anti-VEGF strategy is not necessarily effective for all patients with DME, suggesting the potential involvement of other molecules in the pathogenesis of DR.
Galectins, an evolutionarily conserved family of galactoside-binding lectin proteins, bind to cell surface glycol-conjugated proteins or lipids, and regulate a myriad of biological reactions without having specific receptors like cytokines do 11 . Galectin-1, encoded by the LGALS1 gene, contributes to cell adhesion/proliferation and immunosuppression in a variety of cancer cells and regulatory T lymphocytes, respectively 12, 13 . Recently, we and others have revealed that galectin-1 interacts with the N-glycans of VEGFR2, enhancing phosphorylation of VEGFR2 and activating its downstream signal transduction in endothelial cells, so as to promote hypoxia-induced angiogenesis 14, 15 , together with VEGFR1-mediated vascular hyperpermeability 16 . Importantly, vitreous aspirates from eyes with PDR showed higher protein levels of galectin-1 than those from non-diabetic controls 15 . Moreover, the elevated levels of galectin-1 were not correlated with VEGF levels also increased in PDR eyes, suggesting that these two pro-angiogenic molecules are independently regulated 15 .
In this study, we investigated protein levels of galectin-1 in eyes with the different clinical stages of DR, and explored upstream regulatory stimuli for hypoxia-unrelated galectin-1 expression selectively in the pathogenesis of DR but not non-diabetic retinal vascular occlusions.
Results

Elevation of Galectin-1 Protein Levels Selectively in Eyes with DR.
We previously reported that galectin-1 levels significantly increased in the vitreous fluid of PDR eyes compared with non-diabetic controls (idiopathic macular hole and epiretinal membrane) 15 . To further investigate the involvement of galectin-1 in the worsening course of DR, we performed enzyme-linked immunosorbent assay (ELISA) experiments to measure galectin-1 protein levels in aqueous humor samples collected from DR eyes with different clinical stages of DME, PDR, and NVG and from control eyes of non-diabetic, age-matched subjects with cataract (CAT) alone. Galectin-1 protein levels in eyes with DME (3.23 ± 0.42 ng/ml), PDR (6.74 ± 1.67 ng/ml) and NVG (13.58 ± 2.59 ng/ml) were significantly higher than those with CAT (1.63 ± 0.46 ng/ml) (Fig. 1A) . Galectin-1 protein levels showed a soaring rise with the progression of clinical stages of DR, in consistence with a recent report with PDR and NVG 17 . However, ours is the first to show the elevated levels of galectin-1 in eyes with DME, a hallmark of diabetic microvascular inflammation at the pre-ischemic stage prior to the angiogenic stages of PDR and NVG. In addition, we evaluated galectin-1 protein levels in aqueous humor samples collected from eyes with macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Interestingly, these non-diabetic retinal vaso-occlusive diseases showed no significant differences in galectin-1 protein levels compared with CAT (BRVO, 1.64 ± 0.28 ng/ml; CRVO, 2.44 ± 0.67 ng/ml) (Fig. 1A) , suggesting a potential selectivity for DR in the ischemia-independent regulation of galectin-1. Indeed, the mean galectin-1 levels were still higher in eyes with DME than in those with retinal vein occlusions, showing a statistically significant difference compared to BRVO and a nonsignificant tendency to CRVO (Fig. 1A) .
Consistent with our current and previous results using clinical samples, galectin-1 protein levels gradually increased in the retina of mice with streptozotocin (STZ)-induced diabetes over time (303.7 ± 37.5, 423.7 ± 38.4, 453.8 ± 44.0, 452.4 ± 41.6, and 488.7 ± 67.2 pg/mg at 4, 8, 12, 16 , and 20 weeks after STZ injection, respectively) compared to citrate buffer as a vehicle control (269.3 ± 16.7, 301.4 ± 20.9, 315.5 ± 27.9, 288.5 ± 27.8, and 252.9 ± 16.7 pg/mg at 4, 8, 12, 16, and 20 weeks, respectively) (Fig. 1B) .
Induction of
LGALS1 mRNA Exclusively in IL-1β-Stimulated Müller Glial Cells. Hypoxia-inducible factor (HIF)-1α, a master transcription factor for cellular response to hypoxia, was shown to regulate LGALS1 mRNA expression in cancer cells 13 . Similarly, we recently demonstrated a significant induction of LGALS1 mRNA expression following hypoxic insults to various retinal cells 15 . More recently, ischemia-induced retinal neovascularization in mice was shown to overexpress galectin-1 18 . However, the unelevated galectin-1 levels in eyes with BRVO and CRVO (Fig. 1A) , two representative vaso-occlusive diseases characterized by retinal ischemia 19 , led us to hypothesize a DR-selective regulatory mechanism other than hypoxia. First, we checked high glucose application to 3 major cell types closely associated with the pathogenesis of DR: Müller glial cells (MIO-M1), retinal microvascular endothelial cells (HRMEC), and monocyte-derived macrophages (THP-1).
LGALS1 mRNA levels were unaltered in these cells during culture with 30-mM glucose up to 72 hours in comparison to osmolality-controlled 5-mM glucose at 0 hour ( Fig. 2A-C) .
Next, we extracted the following 4 inflammatory cytokines from the literature [3] [4] [5] [6] [7] : IFN-γ, insulin-like growth factor (IGF)-I, IL-12, and IL-1β; all of which were shown to increase exclusively in eyes with DR but not BRVO or CRVO, as candidate inducers for hypoxia-independent LGALS1 gene expression in these 3 cell lines. Importantly, LGALS1 mRNA levels significantly increased solely after IL-1β stimulation to MIO-M1 (fold change = 1.86) compared to PBS as a vehicle control, but not after any of the other combinations of cytokines and cell types ( Fig. 2D-F) .
Given that Müller glial cells were reported to express VEGF and galectin-1 in fibrovascular tissues in human PDR 15, 20 , we examined the in vitro induction of these two angiogenic factors under hypoxic and IL-1β stimuli to MIO-M1 ( Supplementary Fig. S1 ).
LGALS1 and VEGF165 mRNA levels significantly increased at 6 hours after treatment with IL-1β and hypoxia, respectively. At 24 hours, both molecules were upregulated mainly following either of these stimuli, still showing the preferential induction of LGALS1 by IL-1β and VEGF165 by hypoxia. (Fig. 2D) , we performed additional experiments. IL-1β application to MIO-M1 elevated LGALS1 mRNA levels in a dose-dependent manner (3 ng/ml, fold change = 1.55; 10 ng/ml, fold change = 1.88; 30 ng/ml, fold change = 2.33) (Fig. 3A) . Moreover, the upregulated SCientiFiC REpoRtS | 7: 16168 | DOI:10.1038/s41598-017-16499-8
Galectin-1/LGALS1 Expression in Müller Glial
LGALS1 mRNA expression was suppressed by pretreatment with anti-IL1R1 (IL-1 receptor, type 1) neutralizing antibody (fold change = 1.37) compared to normal IgG treatment (fold change = 1.72) (Fig. 3B) , suggesting a significant contribution of the IL-1β-IL1R1 axis to glial LGALS1 expression. Further, to determine its downstream intracellular signaling, we employed specific inhibitors for extracellular signal-regulated kinase (ERK)1/2 (U0126), phosphatidylinositol-3 kinase (PI3K, LY294002), nuclear factor-κB (NF-κB, JSH-23), c-Jun N-terminal kinase (JNK) (SP600125), and p38 mitogen-activated protein kinase (MAPK) (SB203580). IL-1β-induced LGALS1 mRNA levels were significantly reversed by ERK1/2 or PI3K inhibition (U0126, fold change = 1.27; LY294002, fold change = 1.14), but in contrast significantly augmented by p38 MAPK inhibition (SB203580, fold change = 2.19) (Fig. 3C) . Treatment with SB203580 alone also increased LGALS1 expression ( Supplementary  Fig. S2 ), suggesting the regulation of LGALS1 transcription negatively via p38 MAPK and positively via ERK1/2 and PI3K in Müller glial cells. Additionally, we confirmed the impact of ERK1/2 or PI3K inhibition in protein levels as well (Fig. 3D) .
Next, to confirm the in vitro IL1R1-mediated regulation of LGALS1 mRNA (Fig. 3B ), we performed immunofluorescence analyses to examine the existence of IL1R1 in human samples surgically collected from eyes with PDR. Müller glial cells with glial fibrillary acidic protein (GFAP)-positive signals expressed galectin-1 in fibrovascular tissues 15 . IL1R1 immunoreactivity was strongly positive in the fibrovascular tissue and co-localized with 
AGE-Induced Expression of IL-1β in Macrophages via TLR4 Signaling. Among various biological
pathways involved in the pathogenesis of DR, AGE production has been regarded as one of the main contributors for microvascular complications in diabetes 8, 9 . AGE levels were shown to increase in the vitreous fluid as well as in the serum of patients with DR 21 . Thus we hypothesized AGE as a potential inducer for IL-1β, which was shown to increase in eyes with DR but not non-diabetic retinal vascular occlusions [3] [4] [5] [6] [7] , so as to examine its cellular source in response to AGE-BSA. IL1B mRNA levels were not changed after AGE application to MIO-M1 or HRMEC (Fig. 4A, Supplementary Fig. S4 ), but in stark contrast, THP-1 clearly demonstrated a dose-dependent responsiveness to AGE in IL1B transcripts (10 μg/ml, fold change = 6.95; 50 μg/ml, fold change = 18.04; 200 μg/ml, fold change = 22.94; 400 μg/ml, fold change = 21.93) (Fig. 4B ) and products in culture media (0 μg/ml = 1.49 pg/ml; 10 μg/ml = 16.64 pg/ml; 50 μg/ml = 77.75 pg/ml; 200 μg/ml = 115.69 pg/ml; 400 μg/ml = 107.36 pg/ml) (Fig. 4C) .
AGE has been reported to bind with RAGE (receptor for advanced glycation endproducts) and TLR (toll-like receptor) 4 to activate inflammatory responses in chondrocytes and podocytes 22, 23 . To identify signaling pathways involved in AGE-induced IL-1β production in human macrophages, we carried out blocking experiments. AGE-stimulated IL1B expression was significantly suppressed by pretreatment with anti-TLR4 neutralizing antibody (fold change = 10.01), but not with either anti-RAGE neutralizing antibody (fold change = 18.25) or normal IgG (fold change = 17.64) (Fig. 4D ). We also confirmed that another RAGE inhibition using the RAGE antagonist peptide, RAP (ELKVLMEKEL), did not change IL1B expression (data not shown). MAPK and NF-κB signaling pathways have proven to be involved in AGE-induced inflammatory responses 24 . Pretreatment with JSH-23, U0126 and SP600125 effectively blocked AGE-induced IL1B expression (JSH-23, fold change = 4.12; U0126, fold change = 1.08; SP600125, fold change = 8.92) (Fig. 4E) , suggesting the involvement of NF-κB, ERK1/2 and JNK signaling pathways in IL-1β-expressing macrophages. We also confirmed the impact of ERK1/2 or NF-κB inhibition on protein levels as well (Fig. 4F) . were treated with IFN-γ (100 ng/ml), IGF-I (100 ng/ml), IL-12 (10 ng/ml), and IL-1β (10 ng/ml) for 24 hours, and LGALS1 expression was analyzed. **p < 0.01 (n = 8 per group). was treated with IL-1β (3-30 ng/ml) for 24 hours, and LGALS1 expression was analyzed. (B) MIO-M1 was pretreated with a neutralizing antibody against IL1R1 (10 μg/ml) and control normal IgG (10 μg/ml) for 30 minutes followed by treatment with IL-1β (10 ng/ml) for 24 hours, and LGALS1 gene expression levels were analyzed. (C-D) MIO-M1 was pretreated with each inhibitor at 10 μM for 30 minutes before cultured with IL-1β (10 ng/ml) for 24 hours, and LGALS1 gene and protein expression levels were analyzed. *p < 0.05, **p < 0.01 (n = 8 per group). Full-length blots are presented in Supplementary Fig. S3 . (E-G) Double labeling of GFAP (green), IL1R1 (red) and DAPI (blue) in PDR fibrovascular tissues. (H-J) Double labeling of galectin-1 (green), IL1R1 (red) and DAPI (blue) in PDR fibrovascular tissues. Scale bar = 25 μm.
SCientiFiC REpoRtS | 7: 16168 | DOI:10.1038/s41598-017-16499-8 AGE-Induced Expression of Galectin-1 via Cellular and Molecular Inflammatory Cues. To test a potential requirement of cellular (macrophage) and molecular (IL-1β) inflammatory cues in the DR-selective elevation of galectin-1 (Fig. 1A) , we performed in vitro (Fig. 5 ) and in vivo (Fig. 6) experiments. In vitro, we investigated the effect of AGE-treated THP-1 culture supernatant on galectin-1/LGALS1 expression in MIO-M1 (Fig. 5A) , in order to recapitulate a pathological link between macrophages and Müller glial cells leading to galectin-1 production. Importantly, LGALS1 mRNA expression was not altered following AGE administration directly to MIO-M1, HRMEC or THP-1 (Fig. 5B-D) , while MIO-M1 applied with AGE-treated THP-1 culture supernatant led to a dose-dependent upregulation in LGALS1 transcripts (10 μg/ml, fold change = 1.28; 50 μg/ ml, fold change = 1.39; 200 μg/ml, fold change = 1.61; 400 μg/ml, fold change = 2.05) (Fig. 5E ) and products in cell lysates (Fig. 5F ), and galectin-1 secretion into culture media (0 μg/ml = 7.73 ng/ml; 10 μg/ml = 8.02 ng/ml; Figure 4 . AGE-induced expression of IL-1β in macrophages via TLR4 signaling. (A) MIO-M1 was treated with AGE-BSA (10-400 μg/ml) for 24 hours, and IL1B expression levels were analyzed. (B,C) THP-1 was treated with AGE-BSA (10-400 μg/ml) for 24 hours, and IL1B gene expression levels in cell lysates (B) and IL-1β protein levels in culture media (C) were analyzed. (D) THP-1 was pretreated with neutralizing antibodies against RAGE (10 μg/ml) and TLR4 (10 μg/ml), in comparison with control normal IgG (10 μg/ml) for 30 minutes followed by treatment with AGE-BSA (50 μg/ml) for 24 hours, and IL1B gene expression levels were analyzed. (E,F) THP-1 was pretreated with each inhibitor at 10 μM 30 minutes before application with AGE-BSA (50 μg/ml) for 24 hours, and IL1B mRNA (E) and protein (F) expression levels were analyzed. **p < 0.01 (n = 8 per group). Full-length blots are presented in Supplementary Fig. S5 . LGALS1 gene (E) and protein ((F), cell lysates; (G), culture media) expression (n = 8 per group). Full-length blots are presented in Supplementary Fig. S6 . (H) MIO-M1 was pretreated with a neutralizing antibody against IL1R1 (10 μg/ml) and control normal IgG (10 μg/ml) for 30 minutes, followed by treatment with AGE-BSA-stimulated THP-1 culture medium for 48 hours, and processed for LGALS1 gene expression. (I,J) THP-1 was directly treated with AGE-BSA (10-400 μg/ml) for 24 hours, and processed for IL6 (I) and TNFA (J) gene expression. ND, not detected. (K-M) MIO-M1 (K) HRMEC (L) and THP-1 (M) were treated with IL-6 (10 ng/ml) and TNF-α (10 ng/ml) for 24 hours, and LGALS1 expression was analyzed. *p < 0.05, **p < 0.01 (n = 6 per group). (L) Murine primary microglia was pretreated with a neutralizing antibody against Tlr4 (10 μg/ml), in comparison with PBS or control normal IgG (10 μg/ml) for 30 minutes followed by treatment with AGE-BSA (50 μg/ml) for 24 hours, and Il1b gene expression levels were analyzed. *p < 0.05, **p < 0.01 (n = 6 per group). (M-O) Double labeling of Il-1β (green), Iba-1 (red) and DAPI (blue) in the retina of mice with STZ-induced diabetes at 2 months. Scale bar = 40 μm.
50 μg/ml = 10.57 ng/ml; 200 μg/ml = 12.50 ng/ml; 400 μg/ml = 15.32 ng/ml) (Fig. 5G) . Moreover, the upregulated LGALS1 mRNA expression was suppressed by pretreatment with anti-IL1R1 neutralizing antibody (fold change = 1.14) compared to normal IgG treatment (fold change = 1.50) (Fig. 5H) , suggesting the requirement of IL-1β secreted from AGE-stimulated macrophages to induce LGALS1 expression in Müller glial cells.
Since AGE has been shown to induce various inflammatory responses in diabetes, we checked two representative cytokines IL-6 and tumor necrosis factor (TNF)-α, both of which are classically known to be associated with the pathogenesis of DR, in addition to IL-1β. AGE stimulation to THP-1 led to significant increases in mRNA expression levels of both IL6 (0 μg/ml, not detected; 10 μg/ml, not detected; 50 μg/ml, fold change = 1.00; 200 μg/ ml, fold change = 3.93; 400 μg/ml, fold change = 3.84) (Fig. 5I) and TNFA (10 μg/ml, fold change = 5.76; 50 μg/ml, fold change = 14.27; 200 μg/ml, fold change = 17.19; 400 μg/ml, fold change = 16.21) (Fig. 5J) ; however, LGALS1 expression was not induced by either of the two cytokines in any of the cell lines MIO-M1, HRMEC or THP-1 (Fig. 5K-M) , in consistence with the almost complete suppression of upregulated LGALS1 mRNA levels achieved by anti-IL1R1 neutralizing antibody (Fig. 5H) .
Diabetes-Induced Expression of Retinal Lgals1 via AGE-Triggered Inflammatory Cues. To fur-
ther confirm whether the AGE-triggered inflammatory cues (Fig. 5H) are required for diabetes-induced retinal production of galectin-1 in mice (Fig. 1B) , we performed the in vivo inhibition of AGE generation with aminoguanidine 25 . AGE accumulation in tissues including the retina was shown to be detected after 6 weeks of diabetes, and AGE inhibition attenuated pathological changes in mice at 8 weeks of diabetes [26] [27] [28] , leading us to fix the evaluation point of 2 months after STZ injection in the following experiments. Lgals1 expression levels increased in the retina of mice with STZ-induced diabetes at 2 months compared to citrate buffer as a vehicle control (fold change = 3.16) (Fig. 6A ), in accordance with the elevated protein concentration (Fig. 1B) . Retinal Il1b expression levels also increased compared to a vehicle control (fold change = 5.39) (Fig. 6B) , consistent with previous data on Il-1β production in diabetic rats 29 . Importantly, treatment with aminoguanidine (AG) led to significant suppression of both Lgals1 (fold change = 1.19) and Il1b (fold change = 2.47) mRNA levels upregulated in the diabetic retina (Fig. 6A,B) .
Next, in order to verify the requirement of IL-1β-secreting macrophages for glial production of galectin-1 ( Fig. 5E-H) , we assessed the effect of clodronate liposomes, which diminishes monocyte-derived macrophages 30, 31 , on the retinal gene expression of Lgals1 and Il1b in diabetic mice. Intraperitoneal application with clodronate liposomes (L-Clod) significantly downregulated retinal Lgals1 (fold change = 1.16) and Il1b (fold change = 3.43) mRNA levels compared to treatment with PBS liposomes (L-PBS) (Lgals1, fold change = 4.16; Il1b, fold change = 6.77) (Fig. 6C,D) .
In addition, we carried out antibody-based blockade of Il-1β and Tlr4 to validate the association of these macrophage-related molecules (Fig. 4D ) with diabetes-induced Lgals1 expression in the mouse retina. Intravitreal injections of anti-Il-1β and anti-Tlr4 neutralizing antibodies to animals with STZ-induced diabetes significantly reduced retinal Lgals1 expression (anti-Il-1β, fold change = 1.96; anti-Tlr4, fold change = 1.41) compared to normal IgG treatment (fold change = 3.55) (Fig. 6E) . These results suggested that AGE accumulation in diabetes initiates IL-1β-related inflammatory cues in macrophages followed by retinal galectin-1 upregulation.
To further investigate protein expression and tissue localization of Il-1β and galectin-1 in the retina of mice with STZ-induced diabetes, we performed double-staining immunofluorescence. Il-1β signal co-localized with CD45, a panleukocyte marker, around the ganglion cell layer (GCL) harboring the retinal vasculature (Fig. 6F-H ), in consistence with the current data on IL1B and IL-1β expression in monocyte-derived macrophages (Fig. 4B-F) . Galectin-1 immunoreactivity largely corresponded with the vertical (i.e., antero-posterior) extension of Müller cell processes throughout the entire retina, which were clearly stained with a Müller glial marker glutamine synthetase (GS) (Fig. 6I-K (Fig. 3E-J) . In agreement with changes in mRNA expression levels ( Fig. 6A-E) , both of Il-1β and galectin-1 protein signals were substantially diminished back to nearly normal levels after each treatment (data not shown).
In addition to monocyte-derived infiltrating macrophages, clodronate liposomes eliminate retinal and vitreal resident macrophages (i.e., microglia and hyalocytes, respectively) as well 31, 32 , and microglial activation has also proven to be closely associated with diabetes-induced retinal inflammation 33, 34 . Thus we investigated the possible involvement of microglia in the inhibitory effect of clodronate liposomes on diabetes-induced Il1b expression (Fig. 6D) , using murine microglial primary cell culture stimulated with AGE-BSA. Importantly, Il1b mRNA levels significantly increased after AGE application to microglial cells (fold change = 2.13), which was almost completely inhibited by pretreatment with anti-Tlr4 neutralizing antibody (fold change = 0.93), but not with normal IgG (fold change = 1.84) (Fig. 6L) . In the retina of mice with STZ-induced diabetes, Il-1β signal co-localized with ionized calcium-binding adapter molecule 1 (Iba-1), a microglial marker, mainly at the GCL (Fig. 6M-O) , the site of predilection for retinal microglial cells activated by induction of diabetes to rats 35, 36 .
Tissue Co-localization of AGE, TLR4 and IL-1β in Macrophages. To examine the tissue localization and expression of AGE, TLR4 and IL-1β, we carried out immunofluorescence for fibrovascular tissues surgically excised from human PDR eyes. Double-staining experiments demonstrated co-localization of AGE with CD68 ( Fig. 7A-C) , AGE with TLR4 ( Fig. 7D-F) , IL-1β with CD68 ( Fig. 7G-I) , and IL-1β with TLR4 (Fig. 7J-L) in the proliferative tissue, suggesting the AGE-induced production of IL-1β protein via TLR4 signaling in infiltrating macrophages, in concert with the current in vitro and in vivo data on TLR4-mediated IL1B expression in THP-1 (Fig. 4D) and AGE-induced Il1b expression in macrophages (Fig. 6B,D) . We also confirmed tissue mRNA expression of TLR4, IL1B and IL1R1 (Fig. 7M) .
Discussion
The present study revealed several important findings on the hypoxia-unrelated induction of galectin-1 selectively in the pathogenesis of DR but not non-diabetic retinopathies. Intracameral levels of galectin-1 protein were shown to increase in DR patients concurrently with the aggravation of clinical stages, but not in patients with other non-diabetic retinal vaso-occlusive diseases (Fig. 1) (Figs 2, 3) . AGE stimulation induced the expression of IL-1β through TLR4 activation and its downstream NF-κB, ERK1/2 and JNK signal transduction in human monocyte-derived macrophages (Fig. 4) . Importantly, galectin-1/LGALS1 expression was significantly elevated in Müller glial cells applied with AGE-stimulated macrophage culture supernatant, but not in Müller glial cells directly treated with AGE (Fig. 5) . In vivo inhibition of AGE generation with aminoguanidine, depletion of macrophages with clodronate liposomes, and antibody-based blockade of Il-1β and Tlr4 significantly attenuated diabetes-induced retinal Lgals1 expression in mice (Fig. 6) . Induction of diabetes to mice facilitated retinal Il-1β production in Iba-1-positive resident macrophages (i.e., microglia), and AGE stimulation to murine microglial cells upregulated Il-1b expression via Tlr4 (Fig. 6) . Immunofluorescence analyses showed co-localization of galectin-1 and IL1R1 in GFAP-positive glial cells (Fig. 3) and AGE, TLR4 and IL-1β in CD68-positive macrophages (Fig. 7) in fibrovascular tissues collected from PDR patients. These results suggest that diabetes-induced AGE accumulation activates cellular (macrophage) and molecular (IL-1β) inflammatory cues linking to glial galectin-1 production (Fig. 8) , explaining the DR-selective elevation of galectin-1 along with disease activity beginning from the pre-ischemic stage of DME (Fig. 1) .
During long-standing hyperglycemia in diabetes, excessive glucose forms covalent adducts with proteins gradually through a non-enzymatic process known as glycation. Increasing evidence has shown that hyperglycemia-induced AGE generation and subsequent activation of its receptors RAGE and TLR4 are involved in diabetic complications 24 , facilitating inflammatory and angiogenic processes 22, [37] [38] [39] . In patients with DR, intraocular AGE accumulation has been suggested to contribute to disease onset and progression 21, 40 . AGE-mediated stimulation of TLR4 was shown to induce signaling cascades such as ERK1/2 and NF-κB, triggering the release of pro-inflammatory cytokines and chemokines including IL-1β, IL-6, and TNF-α 22, 41 . In concert with previous in vivo data showing the involvement of TLR4 42 and IL-1β 43, 44 in diabetes-induced retinal inflammation and microvascular injury, our current in vitro and in vivo results as well as human data highlighted the significance of AGE-TLR4 signaling pathway to induce IL-1β in monocyte-derived macrophages and microglial cells (Figs 4, 6, 7) , which was required for upregulation of galectin-1 in Müller glial cells (Figs 2, 3, 5 ). Although we and others already showed increased levels of galectin-1 in PDR 15 and NVG 17 , this AGE-initiated inflammatory mechanism, which exists prior to the angiogenic stages of PDR and NVG, may explain the currently observed induction of galectin-1 in the earlier stage of DME (Fig. 1) .
Recently, galectin-1 has been shown to recognize the N-glycans on VEGFR2, and regarded as a novel VEGFR2 ligand and endothelial cell mitogen 14, 15 . Importantly, vitreous aspirates from PDR patients showed elevated levels of galectin-1 protein, which was not correlated with VEGF levels also elevated in the same individual samples, suggesting that these two molecules were independently regulated 15 . This is consistent with the current data showing the unelevated levels of galectin-1 in non-diabetic retinal vascular occlusions CRVO and BRVO (Fig. 1) , both of which are governed by hypoxia-induced VEGF. Moreover, the present in vitro findings contrasted these two VEGFR2 ligands in terms of the preferential gene upregulation of LGALS1 by IL-1β and VEGF165 by hypoxia in Müller glial cells ( Supplementary Fig. S1 ), which are activated in various retinal diseases. These findings emphasize that DR, another retinal vaso-occlusive disease, is a more complex clinical entity complicated by chronic and progressive microvascular abnormalities mediated by hyperglycemia-associated AGE in addition to hypoxia-induced VEGF.
Supporting our recent data showing the dissociation between VEGF and galectin-1 in PDR 15 , we confirmed the substantially different regulation of VEGF165 mRNA expression in glial cells, vascular endothelial cells and macrophages treated with various DR-related stimuli ( Supplementary Fig. S8 ) as compared with the current LGALS1 data (Figs 2 and 5B-D) . In anti-VEGF refractory tumors, galectin-1 secretion increased together with its enhanced binding to neovascular endothelial cells due to altered glycosylation patterns on VEGFR2 (i.e., decreased α2,6-linked sialic acid), leading to galectin-1-driven angiogenesis and tumor progression 14 . We have shown a significant increase in the total amount of N-glycans in PDR eyes, whereas α2,6-linked sialic acid was relatively decreased in glucose-stimulated human retinal vascular endothelial cells 45 . Based on these findings, the microenvironment of N-glycan profile in PDR eyes is suggested to facilitate the interaction of galectin-1 with VEGFR2, thus enhancing the function of galectin-1 as an angiogenic factor and elaborately escaping from anti-VEGF therapeutic efficacy.
This study has some limitations. The currently measured BRVO and CRVO samples were limited to those from eyes with macular edema but no retinal neovascularization. Although macular edema due to retinal vein occlusions appears to result mainly from ischemia-induced VEGF, it remains largely unclear why these retinal vaso-occlusive diseases failed to show elevated levels of ischemia-induced galectin-1. It is reasonable to speculate that the more advanced stages of CRVO and BRVO would exhibit higher levels of ischemia-induced galectin-1, which is also thought to contribute to the soaring rise in galectin-1 along with the severity of DR (Fig. 1A) on top of AGE-triggered galectin-1. Finally, the currently assessed cell types (i.e., Müller glia, vascular endothelial cells, monocyte-derived macrophages, and microglia) did not represent all the cellular participants in the pathogenesis of DR; therefore, we could not exclude the possibility of other cellular pathways leading to galectin-1 expression in the pathogenesis of DR.
In summary, diabetes-induced generation and accumulation of AGE were suggested to activate IL-1β-related inflammatory cues in monocyte-derived macrophages/microglia followed by Müller glia, linking to the upregulation of galectin-1 (Fig. 8) along with the severity of DR (Fig. 1) . The present data underscore the inflammatory mechanism underlying the selective upregulation of galectin-1 in DR but not in non-diabetic, AGE-unrelated retinal vaso-occlusive diseases.
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Methods
Reagents. The following antibodies were used: rabbit anti-galectin-1 (for human) and rabbit anti-AGE, Abcam (Cambrige, MA); mouse anti-CD68, mouse anti-TLR4 (for human), and rat anti-Tlr4 (for mouse), Affimetrix (Santa Clara, CA); mouse anti-GFAP, Leica (Exton, PA); rabbit anti-IL-1β (for human and mouse), Santa Cruz Biotechnology (Santa Cruz, CA); goat anti-Il-1β (for mouse), goat anti-IL1R1, mouse anti-RAGE, goat anti-galectin-1 (for mouse), and normal goat, mouse and rat IgGs, R&D Systems (Minneapolis, MN); rat anti-CD45, BD Biosciences (San Jose, CA); mouse anti-GS, Millipore (Temecula, CA); mouse anti-Iba-1, Wako Pure Chemical Industries (Osaka, Japan); rabbit anti-β-actin, Medical & Biological Laboratories (Nagoya, Japan); horseradish peroxidase-conjugated anti-rabbit IgG, Jackson ImmunoResearch Laboratories (West Grove, PA); AlexaFluor-conjugated anti-mouse, rabbit, rat and goat IgGs, Thermo Fisher Scientific (Waltham, MA). As for the anti-AGE antibody, both AGE-BSA and AGE-HSA (human serum albumin) are antigens immunized in rabbits to induce polyclonal antibodies, which the manufacturer confirmed can detect both AGE-BSA and AGE-HSA properly, showing minimal (<1%) cross reactivity with BSA and HSA. We further verified the specific Figure 8 . A schema showing the involvement of AGE-triggered inflammatory cues linking to galectin-1 upregulation in the pathogenesis of DR. AGE accumulation due to prolonged hyperglycemia triggers cellular (macrophage) and molecular (IL-1β) inflammatory cues linking to glial galectin-1 production, explaining the DR-selective elevation of galectin-1 along with disease activity (Fig. 1A) . Galectin-1 binds to VEGFR1 and VEGFR2 in endothelial cells, leading to vascular leakage 16 and angiogenesis 14, 15 , respectively.
